<span item_type="fundamental" item_id="f9a334bfbc8f08da83cbae9d927ef11b" counter_id="ST/US/BIAF" env="prod"></span><span item_type="announcement" item_id="582682176723623041" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 1.446 M, beating the estimate of USD 1.411 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -4.74, missing the estimate of USD -2.7.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.289 M, beating the estimate of USD -2.735 M.</p><p></p><h3>Segment Revenue</h3><ul><li>CyPath® Lung revenues increased 86% year over year for the first nine months of 2025, driven by higher test volumes and growing clinical adoption, including the Veterans Administration (VA).<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Sales of CyPath® Lung reached a record high in the third quarter of 2025, representing a 92% increase over the previous quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Total revenues decreased from $2.4 million to $1.5 million for the three months ended September 30, 2025, due to the strategic decision to discontinue unprofitable pathology services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating expenses for the third quarter of 2025 were $3.7 million, down 16% from $4.3 million in the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Direct costs and expenses were $0.9 million, a 38% decrease from the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Research and development expenses increased 20% year-over-year to $330,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Clinical development expenses increased to $143,000, up from $94,000 in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Selling, general and administrative expenses decreased 7% to $2.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Depreciation and amortization expense declined 25% year-over-year to $113,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Net loss for the three months ended September 30, 2025, was $5.1 million, compared with a net loss of $2.0 million for the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash and cash equivalents as of September 30, 2025, were $7.7 million, compared with $1.1 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>Raised aggregate gross proceeds of $10.4 million from equity transactions in the third quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The number of CyPath® Lung tests processed increased by 97% over the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company is focusing on driving the adoption of CyPath® Lung while maintaining fiscal discipline, with strategic actions to streamline laboratory operations and reduce costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>The expansion of the intellectual property portfolio with a new U.S. patent is expected to protect the diagnostic algorithm and test method used to detect lung cancer.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li><li>The company anticipates continued growth in clinical adoption and market expansion, particularly in the mid-Atlantic region and VA hospitals.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/ex99-1.htm"></span></li></ul>

bioAffinity Tech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.446 M